“A.G.E.S. Fall Conference” on BrightU: How a controversial fecal transplant quietly reversed autism in nonverbal twins

• On Day 3 of “A.G.E.S. Fall Conference Docuseries,” Dr. Sabine Hazan presented an FDA-monitored case where microbiome restoration therapy made nonverbal autistic twins fully verbal readers within nine months.
• The treatment eradicated harmful gut bacteria and transplanted donor microbiota, dramatically increasing protective bifidobacteria to match the donor’s profile.
• Standard autism assessment scores showed significant improvement, building on Hazan’s prior success with a separate severe autism case.
• Hazan argued the therapy suggests some neurological conditions may be treatable via the gut, challenging established dogma.
• A regulatory battle looms as Hazan seeks FDA approval for a larger study, fearing the natural procedure could become an expensive, inaccessible pharmaceutical.

On Day 3 of “A.G.E.S. Fall Conference Docuseries,” aired on Feb. 23, gastroenterologist and microbiome researcher Dr. Sabine Hazan presented the groundbreaking result of a stunning case study monitored by the U.S. Food and Drug Administration (FDA) about a pioneering microbiome restoration therapy that enabled identical, nonverbal autistic twins to become fully verbal readers within nine months.

The treatment, which involved eradicating harmful gut bacteria and fostering beneficial ones, resulted in dramatic clinical improvements and matched the twins’ gut profiles to their healthy donor’s, reigniting a fierce debate over the future of this affordable procedure. Hazan detailed the FDA-monitored protocol, which she calls “the art of refloralization.”

The process involved carefully screening a donor’s stool, eradicating pathogenic “bad bugs” in the twins and then transplanting the donor’s microbiota to restore a healthy gut balance, with a particular focus on boosting protective bifidobacteria. “These kids were nonverbal, two identical twins,” Hazan told the audience. “They’re reading Junie B. Jones and they’re fully verbal nine months after treatment.”

The data revealed a profound microbial shift. At the start, the twins had nearly identical, dysregulated gut profiles. After nine months of treatment, the harmful microbes had disappeared and their gut ecosystems transformed. Crucially, levels of bifidobacteria, a genus of bacteria Hazan calls essential for health, soared to 55% in one twin and 7% in the other, mirroring their donor’s profile.

According to BrightU.AI‘s Enoch, bifidobacteria are beneficial, gram-positive anaerobic bacteria that naturally inhabit the human colon, producing acetic and lactic acid. They are especially abundant in breast-fed infants and their population typically remains stable until old age.

“Find the bug, kill the bug, restore the microbiome,” Hazan said, outlining her philosophy. She emphasized that the treatment was not a crude fecal transplant but a targeted microbial restoration. The clinical outcomes were quantified using standard autism assessments (ATEC and CARS scores), which showed significant improvement.

This case builds on Hazan’s earlier work, including a separate study of a 19-year-old with severe autism. After a transplant from his sister, his aggressive behavior and head-banging ceased and he began to speak. “He started saying mama, baba. He’s no longer aggressive,” she reported. His gut diversity score jumped from 2.2 to match his sister’s 6.7 and damaging proteobacteria “essentially disappeared.”

The implications are vast, suggesting a paradigm where some neurological conditions may be treatable via the gut. “Maybe Alzheimer’s is not a brain problem. It might be a gut problem,” Hazan mused, referencing another case where a fecal transplant improved an Alzheimer’s patient’s memory.

However, a major regulatory battle looms. Hazan’s protocol exists in a gray area. She is now fundraising for a larger, FDA-approved study on 30 autistic patients using familial donor material. The fear among advocates is that if proven effective, this natural procedure could be co-opted and classified as a pharmaceutical drug, putting it behind a wall of high costs and limited access.

“I believe there’s a role for pharmaceutical product. However, there’s also a role for if I want my grandchild’s poop, then I should be allowed to have my grandchild’s poop instead of a stranger that I don’t know,” Hazan argued, highlighting the tension between medicalization and patient autonomy.

She issued a strong warning against attempting “do-it-yourself” versions, citing risks of serious infection or death. “Please do not do fecal transplant at home. You could kill yourself.” As the research advances, this “gut shot” approach challenges decades of neurological dogma. With a passionate researcher bridging alternative and mainstream medicine, and the FDA cautiously engaged, the treatment of autism and other complex conditions may be on the cusp of a radical, if contentious, revolution.

Want to learn more?

The A.G.E.S. doctors have come together not to sell you fear, but to hand you the tools, knowledge and confidence to become the architect of your own vitality. If you are ready to stop collecting fragments of the solution, it’s time to own the masterplan. Purchase the “A.G.E.S. Fall Conference Docuseries” full package here.

Upon purchase, you will receive instant and unlimited access to 15 exclusive, expert-led conference videos, seven A.G.E.S Family Q&A session videos, downloadable presentation PDFs and full transcription PDF for every video.

BrighteonUniversity.com 1

BrighteonUniversity.com 2

BrightU.com